Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

This analysis (7 RCTs; n=7287) noted that, when added to ADT, treatments associated with significantly improved overall survival included abiraterone acetate (HR 0.61; 95% CI 0.54-0.70), apalutamide (0.67; 0.51-0.89), and docetaxel (0.79; 0.71-0.89).

SPS commentary:

Although enzalutamide was associated with improved radiographic progression-free survival when added to androgen deprivation therapy (HR 0.39; 95% CI 0.30-0.50), longer follow-up is needed to examine its overall survival benefits.

JAMA Oncology